Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
2.80% $0.770
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 10.49 mill |
EPS: | -2.94 |
P/E: | -0.260 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 13.62 mill |
Avg Daily Volume: | 0.244 mill |
RATING 2024-03-27 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.260 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -0.260 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.764 (-0.79%) $-0.0061 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 0.710 - 0.830 ( +/- 7.79%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-14 | Darvish Nissim | Buy | 20 572 | Option to Purchase American Depositary Shares |
2021-04-19 | Darvish Nissim | Buy | 11 884 | Option to Purchase American Depositary Shares |
2016-10-28 | Darvish Nissim | Buy | 10 123 | Option to Purchase American Depositary Shares |
2023-03-16 | Darvish Nissim | Buy | 6 857 | Option to Purchase American Depositary Shares |
2022-03-07 | Darvish Nissim | Buy | 6 820 | Option to Purchase American Depositary Shares |
INSIDER POWER |
---|
-56.89 |
Last 88 transactions |
Buy: 2 375 207 | Sell: 4 584 307 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.770 (2.80% ) |
Volume | 0.0480 mill |
Avg. Vol. | 0.244 mill |
% of Avg. Vol | 19.71 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.